Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention A Contemporary Review by Dewilde, Willem J.M. et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 4 , N O . 1 2 , 2 0 1 4
ª 2 0 1 4 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 0 6 . 1 1 9 3THE PRESENT AND FUTURE
STATE-OF-THE-ART REVIEWTriple Therapy for Atrial Fibrillation and
Percutaneous Coronary Intervention
A Contemporary ReviewWillem J.M. Dewilde, MD,* Paul W.A. Janssen, MD,y Freek W.A. Verheugt, MD, PHD,z
Robert F. Storey, MD, PHD,x Tom Adriaenssens, MD, PHD,k Morten L. Hansen, MD, PHD,{
Morten Lamberts, MD, PHD,{ Jurriën M. ten Berg, MD, PHDyABSTRACTFro
Ni
xD
thu
Ge
co
fee
Re
rec
co
MaChronic oral anticoagulant therapy is recommended (class I) in patients with mechanical heart valves and in patients with
atrial ﬁbrillation with a CHA2DS2-VASc (Congestive heart failure, Hypertension, Age $75 years, Diabetes mellitus, prior
Stroke or transient ischemic attack or thromboembolism, Vascular disease, Age 65 to 74 years, Sex category) score $1.
When these patients undergo percutaneous coronary intervention with stenting, treatment with aspirin and a P2Y12
receptor inhibitor also becomes indicated. Before 2014, guidelines recommended the use of triple therapy (vitamin K
antagonists, aspirin, and clopidogrel) for these patients. However, major bleeding is increasingly recognized as the
Achilles’ heel of the triple therapy regimen. Lately, various studies have investigated this topic, including a prospective
randomized trial, and the evidence for adding aspirin to the regimen of vitamin K antagonists and clopidogrel seems to be
weakened. In this group of patients, the challenge is ﬁnding the optimal equilibrium to prevent thromboembolic
events, such as stent thrombosis and thromboembolic stroke, without increasing bleeding risk. (J Am Coll Cardiol
2014;64:1270–80) © 2014 by the American College of Cardiology Foundation.C hronic oral anticoagulation (OAC) is neces-sary in patients with mechanical heartvalves and in patients with atrial ﬁbrillation
(AF) and a CHA2DS2VASc (Congestive heart failure,
Hypertension, Age $75 years, Diabetes mellitus, prior
Stroke or transient ischemic attack or thromboembo-
lism, Vascular disease, Age 65 to 74 years, Sex cate-
gory) score $1 (1,2). About 30% of these patients
have concomitant coronary artery disease (CAD).
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In a rapidly aging population, the number of pa-
tients experiencing both AF and CAD is steadily
increasing. However, triple therapy produces a high
annual bleeding risk of up to 45%, and an association
has been seen among major bleeding events, blood
transfusion, and increased mortality risk (6–11). Triple
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AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome(s)
AF = atrial ﬁbrillation
BARC = Bleeding Academic
Research Consortium
DAPT = dual antiplatelet
therapy
LMWH = low molecular weight
heparin
OAC = oral anticoagulation
PCI = percutaneous coronary
intervention
PPI = proton pump inhibitor
TIMI = Thrombolysis In
Myocardial Infarction
TVR = target vessel
revascularization
UFH = unfractionated heparin
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1271possible), was recommend by the 2010 European
guidelines, whereas the recent 2014 North American
Guidelines recommend the combination of VKA and
clopidogrel with a Class IIb, Level of Evidence: B
recommendation (4,12). The 2010 European guidelines
were based on expert opinion and not on randomized
trials (4). Recently, new evidence has emerged sug-
gesting that the increased bleeding risk outweighs the
efﬁcacy (preventing stent thrombosis, myocardial
infarction [MI], stroke, and thromboembolism) beneﬁt
of triple therapy in these patients, and possibly, a new
strategy of VKA and a P2Y12 inhibitor alone could be
preferred (6,12–15). This review will summarize
guidelines, focus on some key evidence from the last
several years, and address unanswered questions.
GUIDELINES
European guidelines recommend triple antithrom-
botic therapy in a patient with AF undergoing PCI
(4). This triple therapy consists of VKA with a
revised target for international normalized ratio (INR)
2.0 to 2.5, aspirin, and clopidogrel. Aspirin has always
been the cornerstone in treating patients with acute
coronary syndrome (ACS) and/or PCI, VKAs are
needed for stroke prevention, and a P2Y12 inhibitor is
essential for the prevention of stent thrombosis
(16–19). However, this triple therapy strategy has
never been studied prospectively until the recent
WOEST (What is the Optimal antiplatElet and anti-
coagulant therapy in patients with oral anti-
coagulation and coronary StenTing) trial (6).
European guidelines recommend continuing VKAs
and giving triple therapy for as short a period as
possible after PCI, in general until stent strut endo-
thelialization is expected to be complete. The dura-
tion of prescribed triple therapy mostly depends on
bleeding risk and stent type, and various recom-
mendations are made to limit bleeding risk, as
mentioned below.
Recently, following the results of the WOEST trial,
the American Heart Association/American College of
Cardiology/Heart Rhythm Society issued a Class IIb
(Level of Evidence: B) recommendation for the
combination of VKA and clopidogrel after PCI in
patients with AF (12).
NEW EVIDENCE
In the randomized, controlled WOEST trial, 573 pa-
tients using VKA undergoing PCI in an open-label,
intention-to-treat design were randomized to either
double therapy (VKA and clopidogrel) or triple ther-
apy (VKA, clopidogrel, and aspirin) (6,20). The pri-
mary endpoint was the occurrence of any bleedingevent. At 1 year, the cumulative incidence of
all Thrombolysis In Myocardial Infarction
(TIMI) bleeding events was 19.4% in the dual-
therapy group compared with 44.4% in pa-
tients treated with triple therapy (hazard
ratio [HR]: 0.36; 95% conﬁdence interval [CI]:
0.26 to 0.50; p < 0.0001) (6,21). The 1-year
incidence of serious bleeding according to
Bleeding Academic Research Consortium
(BARC) criteria 3 also was signiﬁcantly lower
in the dual therapy arm (6.5% vs. 12.7%;
HR: 0.49; 95% CI: 0.28 to 0.86; p ¼ 0.011)
(6,22). Furthermore, dual therapy produced a
signiﬁcantly lower rate of blood transfusions
than did triple therapy (3.9% vs. 9.5%; odds
ratio [OR]: 0.39; 95% CI: 0.17 to 0.84;
p ¼ 0.011). Secondary endpoints included
major adverse cardiac and cerebrovascular
events (MACCE) deﬁned as the composite of
death, MI, stroke, systemic embolism, target
vessel revascularization (TVR), and stent thrombosis,
which occurred in 11.1% of patients receiving dual
therapy compared with 17.6% of patients receiving
triple therapy (HR: 0.60; 95% CI: 0.38 to 0.94;
p ¼ 0.025). The WOEST trial indicates that double
therapy (VKA and clopidogrel without aspirin) sig-
niﬁcantly reduces bleeding complications as com-
pared with triple therapy after PCI in patients with
an indication for OAC. Dropping aspirin in this high-
risk group led to a more than 50% reduction in the
occurrence of bleeding complications.
After the WOEST trial results were published,
expert opinion was that it was too early to change the
guidelines, even though current recommendations
are not based on randomized trials (23). The reasons
given for the reluctance to change guidelines were
based on the limitations of the WOEST trial. First, the
number of patients randomized was relatively low
(n ¼ 573) and not every patient had AF (approxi-
mately 70%). Second, there was no signiﬁcant dif-
ference in TIMI major bleeding, and the absolute
number of major bleeds was rather low (16 vs. 9). The
difference in bleeding was mainly driven by TIMI
minor bleeding. However, when bleeding events
were classiﬁed according to the new standardized
BARC bleeding criteria, there was a signiﬁcant dif-
ference in BARC 3 bleeding, which corresponds with
major bleeding, in favor of the combination of clo-
pidogrel and VKA (6,22). Additionally, the authors
emphasized the importance of minor bleeding,
because these events can lead to cessation of medi-
cation (e.g., clopidogrel) and major adverse events
such as stent thrombosis (6). Third, compared with
current recommendations, the rate of proton pump
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radial approach was used infrequently (26%), bare-
metal stents (BMS) were used in a minority of pa-
tients (31%), periprocedural target INR was 2.0, and
the long-term target INR was not lowered post-
procedurally (target INR 2 to 3 for AF). These results
are compared with current guidelines, which recom-
mend standard PPI use, radial approach, BMS use, and
a lower long-term target INR of 2 to 2.5 in this patient
population. The conﬂict with the guidelines is easily
explained: in 2008, when the WOEST study was
designed, these recommendations were not available
yet (4,12). Fourth, the number of deaths was signiﬁ-
cantly higher with triple therapy, but this was driven
by a higher number of noncardiac deaths, which might
be due to a play of chance. Fifth, there was no infor-
mation on the time of INR in the therapeutic range.
However, we know from the RE-LY (Randomized
Evaluation of Long-Term Anticoagulation Therapy)
trial that the quality of oral anticoagulation is good in
the Netherlands and Belgium, with a therapeutic
range of 65% for patients treated in Belgium and up to
70% in the Netherlands (24). Finally, the study was
not powered to show noninferiority of the secondary
outcomes and the number of patients at high risk of
stent thrombosis, such as those with recent ACS, was
limited to a quarter of the WOEST trial participants.
The study population was heterogeneous, because
the goal was to conduct a trial with a real-life popu-
lation representing daily practice (6). Moreover, the
WOEST trial was the ﬁrst to break the taboo of omit-
ting treatment with aspirin after PCI, hypothesizing
that inhibition of thrombin (a strong platelet acti-
vator) with VKA and inhibition of the P2Y12 receptor
with clopidogrel would make inhibition of cyclo-
oxygenase-1 less important in the protection against
thrombotic and thromboembolic events, particularly
since the P2Y12 receptor plays a major role in ampli-
fying the effects of thromboxane A2.
Recently, a Danish group published results of a real-
life nationwide retrospective registry of 12,165 pa-
tients that supported the ﬁndings in the WOEST trial
(13). The authors investigated the risk for thrombosis
and bleeding according to multiple antithrombotic
regimens after MI or PCI in AF patients. After 1 year,
there was no increased risk of recurrent coronary
events for dual therapy (HR: 0.69; 95% CI: 0.48 to 1.00)
relative to triple therapy, and bleeding risk was also
nonsigniﬁcantly lower for VKA plus clopidogrel (HR:
0.78, 95% CI: 0.55 to 1.12). Moreover, there was a
similar risk for all-cause mortality in patients treated
with VKA plus clopidogrel as well as those receiving
triple therapy, but the combinations of VKA plus
aspirin and aspirin plus clopidogrel were associatedwith a signiﬁcant increase in all-cause mortality
compared with triple therapy (13).
The most important aspect of the Danish registry:
it suggests that the combination of OAC plus clopi-
dogrel is sufﬁcient to reduce the risk of thrombotic
events. This was the missing part of the puzzle, since
the WOEST trial was not powered to show non-
inferiority on the secondary composite MACCE end-
point. Also, the Danish registry is now the second
study in which no beneﬁcial effect of adding aspirin
to VKA and clopidogrel was found in this high-risk
patient group. The authors explain that the bleeding
rate was lower in the VKA plus clopidogrel patient
group, but this difference did not reach statistical
signiﬁcance, likely because this registry only in-
cluded bleeding events serious enough to warrant
hospitalization, whereas all bleeding events were
collected in the WOEST trial.
Two other registries that conﬁrmed the efﬁcacy
and safety of VKA plus clopidogrel in patients with AF
who underwent PCI were recently published. In the
AFCAS (Atrial Fibrillation Undergoing Coronary
Stenting) trial, a prospective nonrandomized study
including 975 patients, the 1-year efﬁcacy and safety
of triple therapy, DAPT, and VKA plus clopidogrel was
comparable (15). A total of 221 patients who received
drug-eluting stenting (DES) were included in another
German registry with a mean follow-up of 19 months.
Despite a shorter period of clopidogrel therapy (6 to
12 months) followed by VKA monotherapy, the com-
bination of OAC plus clopidogrel again appeared both
safe and effective at long-term follow-up (14).
CLINICAL IMPORTANCE AND PREVENTION
OF BLEEDING AFTER PCI
Major bleeding events and blood transfusions have
been associated with increased risk of death in
several studies (7,8,25–28). This has led to an in-
creased awareness of this problem, and predictors
of bleeding events in PCI patients have been identi-
ﬁed. Strong predictors we can inﬂuence are the
choice of vascular access (radial vs. femoral) and the
choice of antithrombotic regimen (28–31).
The importance of bleeding as an adverse event
is underscored by the fact that bleeding has now
become a primary endpoint in many PCI trials
(7,17,28,32,33). In an effort to standardize the deﬁni-
tion and detection of bleeding events in different
studies, the Academic Research Consortium pub-
lished and validated new bleeding criteria (BARC)
(22,34). Before the BARC criteria were established,
different trials used different bleeding deﬁnitions,
which was an important hindrance when trying to
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obstacle when assessing bleeding rates is the possible
under-reporting of bleeding events in studies (36).
Therefore, the impact of bleeding could be even
larger in real life than reported in these studies. This
could also explain why the bleeding rate reported in
the WOEST trial stood very high compared to other
trials, as this study was speciﬁcally designed to
detect bleeding events and data were collected for all
types of bleeding rather than solely focusing on ma-
jor bleeding events (6).
Another issue that needs to be addressed: patients
with AF in need of PCI represent a population that
mainly consists of older patients with high rates
of comorbidity. Many are octogenarians, a group
frequently excluded from or under-represented in
randomized clinical trials. It is questionable whether
our current guidelines can be applied to this group.
Additionally, we know that older patients with AF
have a higher CHA2DS2-VASc score as well as a higher
bleeding risk when treated with VKAs (37). In this
population, the role of nonmajor bleeding should not
be underestimated. Even superﬁcial or “nuisance”
bleeding can lead to discontinuation of antiplatelet
therapy, which can lead to subsequent thrombotic
complications, such as stent thrombosis. Clearly, this
high-risk population, often with multiple comorbid-
ities, is more prone to experience treatment-related
adverse events (4,38).
Over the last years, numerous risk factors have
been associated with higher bleeding risk: age
>55 years, female sex, glomerular ﬁltration rate <60
ml/min, pre-existing anemia, use of low-molecular-
weight heparin (LMWH) <48 h before PCI, use of
glycoprotein IIb/IIIa inhibitors, and the use of an
intra-aortic balloon pump (27,39,40).
To estimate bleeding risk, many bleeding risk–
prediction scores have been proposed, and the best
known is the HAS-BLED score (41). The HAS BLED
score estimates the risk for major bleeding for patients
on anticoagulation and is based on the presence of
some high-risk features as hypertension, stroke, renal
disease, liver disease, prior major bleeding, age older
than 65 years, labile INR, the use of medication pre-
disposing to bleeding and weekly alcohol usage.
Shown to be useful in the assessment of bleeding risk,
the HAS-BLED score also demonstrates some predic-
tive value for cardiovascular events and mortality in
anticoagulated patients with AF. The data are
consistent with the relationship between thrombosis
and bleeding and conﬁrm that the number of bleeding
and thrombotic events is higher in patients with high
comorbidity at baseline (42). The higher the patient’s
bleeding risk, the more measures should be takento avoid and prevent bleeding, such as the standard-
ized use of a risk score assessment tool, a radial
approach, smaller sheath size and early removal, BMS
use, routine use of PPI, utilization of a target INR
range of 2.0 to 2.5, the choice and dose of antith-
rombotics and P2Y12 inhibitors, and avoidance of all of
the following: crossing over from 1 antithrombotic to
another, an intra-aortic balloon pump, use of glyco-
protein IIb/IIIa inhibitors, and periprocedural
bridging with LMWH if not strictly indicated (4,12,28).
PERIPROCEDURAL MANAGEMENT
Besides the choice between dual or triple therapy,
another decision looms for patients on OACwho have a
planned PCI: what to do with the VKA in the peri-
procedural period? In patients on a VKA scheduled for
PCI, the VKA is often discontinued several days prior
to intervention, exposing the patient to a higher risk of
thromboembolic complications. Occasionally, the pe-
riods before and after the intervention are bridged
(until a therapeutic INR is reached) with additional
unfractionated heparin or LMWH, exposing the pa-
tient to excess bleeding risk.When patients are treated
with 4 blood thinners (OAC, clopidogrel, aspirin, and
heparin) for a short period after the intervention until
a therapeutic INR is reached, the bleeding risk is
particularly high (43). Additionally, reinitiation of VKA
may cause a transient prothrombotic state due to
protein C and S suppression (4). Bridging also prolongs
hospitalization, which is unnecessary and wasteful
from an economic point of view.
Recent European guidelines recommended unin-
terrupted VKA as the preferred strategy in patients
with AF undergoing PCI (4). In the AFCAS trial and in
a recent subanalysis of the WOEST trial, uninter-
rupted OAC was not associated with an increased risk
of bleeding or thromboembolic events compared
with bridging therapy (43,44). Furthermore, bleeding
and other adverse events were not associated with
INR levels in these studies (43,44). Additional sup-
port comes from the BAAS (Prospective Balloon
Angioplasty and Anticoagulation) study, where the
combination of aspirin plus VKA compared with
aspirin alone was safe and effective during PCI per-
formed with a target INR of 2.1 to 4.8 (45). So, the
strategy of uninterrupted VKA not only leads to cost
savings, but it is also as safe as bridging and, there-
fore, may be the preferred strategy.
Similarly, the radial approach offers the better
strategy in these patients based on proven lower
rates of bleeding and a possible reduction in mortal-
ity, especially in ST-segment elevation myocardial
infarction patients (30). One question regarding the
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coronary angiography, it might be an option to per-
form PCI without administration of additional
heparin in patients on therapeutic anticoagulation
with a VKA (46). However, physicians did not avoid
an additional heparin bolus during PCI in most
patients included in the WOEST trial. This strategy
was probably chosen due to fear of periprocedural
thromboembolic complications such as stent throm-
bosis (43). On the one hand, this additional heparin
bolus could explain the higher-than-expected
bleeding rates in the original WOEST trial (6). In the
AFCAS study, 48% of patients also received a pre-
procedural bolus of heparin or LMWH in addition
to therapeutic anticoagulation in the uninterrupted
VKA group (44). On the other hand, a recently pub-
lished study showed that the incidence of radial
artery occlusion in patients receiving VKA who un-
dergo transradial coronary angiography is higher in
patients who do not receive an additional standard
intravenous unfractionated heparin bolus (47). As of
yet, there is insufﬁcient evidence to determine if
a heparin bolus is necessary in patients with thera-
peutic INR requiring PCI. Furthermore, it is unclear
what the optimal dosage would be if a heparin bolus
is indeed necessary.
POSSIBLE PITFALLS AND OTHER
UNANSWERED QUESTIONS
In patients treated with triple therapy, bleeding oc-
curs frequently in the gastrointestinal tract, making
protection of the gastric mucosa reasonable. Yet,
some papers have suggested that there is a potential
danger in combining omeprazole and clopidogrel
due to impairment in the formation of the active
metabolite of clopidogrel by omeprazole, leading
to diminished antiplatelet effect (48,49). However,
no clinical consequences of this interaction have
been demonstrated so far. The single randomized
controlled trial on this topic, COGENT (Clopidogrel
and the Optimization of Gastrointestinal Events
Trial), showed that in patients post-ACS, the combi-
nation of omeprazole 20 mg and clopidogrel 75 mg
was superior to the combination of clopidogrel and
placebo in reducing the rate of gastrointestinal
bleeding, with no signiﬁcant difference in the rate of
adverse cardiovascular events (50). Subsequent re-
ports have suggested that PPI use should not be
avoided but rather encouraged in patients on multi-
ple antiplatelet medications (49,51).
A second possible pitfall for clopidogrel is the
wide interindividual variability to the drug, even in
the absence of any drug interactions, with 12% to15% of the variability accounted for by polymorphic
variations in the gene for cytochrome P450 2C19
(52–54). Patients who have a poor inhibitory effect of
clopidogrel and/or carry 1 or more loss-of-function
alleles for cytochrome P450 2C19 are at higher risk
of stent thrombosis, whereas those with a large
inhibitory effect of clopidogrel appear to hold a
higher risk of bleeding. This potentially complicates
the interpretation of data related to dual antiplatelet
therapy with clopidogrel and VKA, because levels of
platelet reactivity may vary widely between patients.
For example, patients with a poor response to clo-
pidogrel who develop a low INR may be at higher risk
of stent thrombosis and other thrombotic events,
whereas patients with a large inhibitory effect of
clopidogrel who develop a high INR may be at higher
risk of bleeding (52–54).
A third conceivable pitfall is the possibility that
VKA itself might modify clopidogrel drug respon-
siveness and efﬁcacy. Both clopidogrel and VKA are
metabolized by the hepatic cytochrome P450 system.
Concomitant phenprocoumon use has been shown to
signiﬁcantly attenuate the antiplatelet effects of
clopidogrel and has been associated with a signiﬁ-
cantly higher level of high on-platelet reactivity
(HPR) (55). While HPR has been linked with a poor
outcome, it is still unknown if the association be-
tween HPR and thrombotic events is as strong in
patients concomitantly treated with coumarin deri-
vates as in patients who do not receive these
drugs. Furthermore, there currently is no evidence
for tailoring antiplatelet therapy based on the pres-
ence of HPR (53). Although switching from clopi-
dogrel to the stronger antiplatelet agents prasugrel or
ticagrelor might be an option in HPR patients without
VKA, it is even more unclear what the optimal
treatment strategy could be for HPR patients with
VKA (53). Theoretically, ticagrelor and prasugrel
could be good alternatives for clopidogrel as they
provide more potent platelet inhibition with less
interindividual variability (56,57). However, bleeding
risk also increases with treatment with ticagrelor
and prasugrel as compared with clopidogrel (56,57).
The fourth and very important question to tackle:
why would we want to replace the combination of
DAPT plus VKA with the combination of VKA plus
clopidogrel? Since 2001, DAPT has been standard
therapy after PCI. The CURE (Clopidogrel in Unstable
Angina to Prevent Recurrent Events) study included
12,562 patients who had presented within 24 h after
ACS without ST-segment elevation and were ran-
domized to receive either clopidogrel or placebo in
addition to aspirin. Clopidogrel had beneﬁcial effects
because of a signiﬁcant reduction in MACCE (9.3% vs.
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CENTRAL ILLUSTRATION Double and Triple Antiplatelet Therapy Risks
in AF and PCI
Patients with atrial ﬁbrillation (AF) who undergo percutaneous coronary intervention
(PCI): combining antiplatelet and anticoagulant therapies in search of an optimal equi-
librium in between bleeding risk on the one hand and thrombotic and thromboembolic
risk on the other.
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127511.4%; p < 0.001) (58). So then, why would we try to
replace aspirin with VKA? In these patients who also
need VKA for stroke prevention, there are many
possible therapeutic combinations, but it has already
been shown that the combination of VKA plus aspirin
(leaving out clopidogrel) led to an increased rate of MI
and stent thrombosis (13,18). In the ACTIVE W (Atrial
Fibrillation Clopidogrel Trial With Irbesartan for Pre-
vention of Vascular Events) study, withholding VKA
(thus treating patients only with aspirin and clopi-
dogrel) in patients with AF led to an increased rate of
cardiovascular events and mortality (16). This leaves
triple therapy and the combination of VKA and clo-
pidogrel as the only alternatives.
But then, why drop aspirin? The hypothesis of the
WOEST trial was that thrombin inhibition with VKA
and inhibition of P2Y12 with clopidogrel would lessen
the importance of cyclo-oxygenase-1 inhibition by
aspirin for protection against thrombotic and throm-
boembolic events, whereas triple therapy has been
associated with an increased risk of both fatal and
nonfatal bleeding (6,7,59,60). This hypothesis was
based on the results of 2 large randomized trials that
compared VKA with aspirin in the prevention of
reinfarction and stroke in patients who had experi-
enced an MI. Vitamin K antagonist treatment was
associated with lower recurrence rates but higher
risks of bleeding in these studies (61,62). Therefore,
VKA seems at least as good as aspirin in protecting
patients from thrombotic events. The hypothesis that
aspirin is not needed in VKA-treated patients who
undergo PCI with stent implantation is supported by
the results of the WOEST trial. Nevertheless, the
WOEST trial was not powered to detect differences in
the occurrence of thrombotic events, such as stent
thrombosis, when aspirin was omitted, and this
would need to be studied in a larger trial. Meanwhile,
these results were conﬁrmed by a large Danish na-
tional registry, the AFCAS trial, and a smaller German
trial all showing favorable results for the combination
of VKA and clopidogrel (6,13–15) (Central Illustration).
The ﬁfth dilemma focuses on how to overcome the
possibility of unopposed thromboxane-dependent
platelet activation after stopping aspirin with subse-
quent cardiovascular events (63). In 2 patient series in
which aspirin monotherapy was stopped without
a substitute, higher rates of thrombotic events
occurred (64,65). Of course, a patient group on aspirin
monotherapy totally differs from the present patients
receiving long-term VKA plus clopidogrel therapy.
Nevertheless, in the WOEST trial, the AFCAS trial, and
the Danish and German registries, there was no
excess of stent thrombosis in the aspirin-free group
(6,13–15). Therefore, it is debatable whether thisunopposed thromboxane-dependent platelet activa-
tion after stopping aspirin is clinically meaningful in
the present patient population. It is possible that the
negative impact of unopposed thromboxane-
dependent platelet activation is overruled by the
anticoagulant effect of VKA and the antiplatelet
effect of clopidogrel.
The sixth unanswered question in patients on
long-term VKA who received a coronary stent is: how
should we treat patients after clopidogrel is dis-
continued (after 3, 6, or 12 months of treatment)? Do
you treat patients with a combination of VKA and
aspirin because of CAD, or is VKA monotherapy
enough to protect patients against thrombotic
events? In the absence of randomized trials, we turn
to 2 large registries: a recently published Danish
registry containing 8,700 patients and ORBIT-AF
(Outcomes Registry for Better Informed Treatment
of Atrial Fibrillation), in which 4,804 patients taking
VKAs were compared with 2,543 patients taking OAC
plus aspirin. In both registries, the combination of
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increased risk for bleeding without a clear reduction
of MACCE (66,67).
The seventh possible pitfall is that the guidelines
recommend BMS placement in both elective and
acute settings for AF patients with an indication for
long-term VKA therapy (4,68). However, these rec-
ommendations were based upon expert opinion in
the absence of data from randomized trials. A recent
subanalysis of the WOEST trial shows no advantage
for patients who received a BMS as compared with a
DES. Moreover, the rate of TVR was signiﬁcantly
lower in patients treated with DES, despite the fact
that baseline characteristics for this group were less
favorable (such as a higher incidence of diabetes at
baseline and more American College of Cardiology/
American Heart Association type C lesions) (unpub-
lished data). We also know that the rates of TVR and
stent thrombosis are markedly lower after implanta-
tion of newer-generation DES, such as everolimus-
eluting stents (69), and the difference in the rate of
stent thrombosis after DES as compared to BMS seems
to have disappeared with the newer-generation DES.
Finally, recent data suggest that 3 months of DAPT
might be long enough in some cases instead of the
standard 12 months. In the recent OPTIMIZE (Opti-
mized Duration of Clopidogrel Therapy Following
Treatment With the Zotarolimus-Eluting Stent in
Real-World Clinical Practice) trial, among 3,199 pa-
tients with stable CAD or low-risk ACS treated with
zotarolimus-eluting stents, 3 months of DAPT was
noninferior to 12 months, without signiﬁcantly in-
creasing the risk of stent thrombosis (70). Moreover,
the EXCELLENT (Efﬁcacy of Xience/Promus Versus
Cypher to Reduce Late Loss After Stenting), PRODIGY
(Prolonging Dual Antiplatelet Treatment After Grad-
ing Stent-Induced Intimal Hyperplasia Study), and
RESET (REal Safety and Efﬁcacy of 3-month dual an-
tiplatelet Therapy following Endeavor zotarolimus-
eluting stent implantation) randomized trials also
tested different durations of DAPT (3 or 6 months vs.
12 or 24 months) with multiple DES, and results did
not show beneﬁts favoring prolonged DAPT (71–74).
One can question if patients on long-term OAC
might beneﬁt from a shorter treatment with clopi-
dogrel that would surely decrease bleeding risk in this
patient group. But, before adopting a regimen con-
taining 3 months of clopidogrel, some caution is
needed. First, a cohort study containing 125,195 pa-
tients showed that the bleeding risk is the highest
during the ﬁrst 30 days of VKA therapy, with almost
1% of all new users admitted to a hospital for hem-
orrhage during this period (37). Second, it is unclear
whether this applies to all DES, as zotarolimus-eluting stents were especially chosen in the OPTI-
MIZE and RESET trials because of their early vessel
healing characteristics (70–74). Third, the OPTIMIZE
trial mostly included patients with stable angina and
low-risk ACS while excluding ST-segment elevation
myocardial infarction patients (70). Therefore it
might be too early to change the duration of routine
clopidogrel administration to 3 months.
NEW MEDICATION, ONGOING TRIALS AND
FUTURE PERSPECTIVES
Although dual therapy with VKA and clopidogrel
probably presents a better option than triple therapy,
there is still much room for improvement with regard
to the prevention of both ischemic and bleeding
events. Therefore, the search for newer and better
antithrombotic medication and combinations of these
drugs continues.
Over the last several years, numerous new medi-
cations have emerged to challenge the classics. In the
PLATO (Study of Platelet Inhibition and Patient Out-
comes) trial evaluating 18,624 patients with ACS, the
combination of ticagrelor (a reversible P2Y12 inhibitor)
and aspirin was superior to clopidogrel and aspirin
(56). Administration of ticagrelor even led to a
decrease in mortality. The TRITON–TIMI 38 (Trial to
Assess Improvement in Therapeutic Outcomes by
Optimizing Platelet Inhibition with Prasugrel–
Thrombolysis In Myocardial Infarction 38) trial
showed that in 13,608 patients with ACS undergoing
PCI, the combination of prasugrel (a more potent
thienopyridine than clopidogrel but similarly an
irreversible P2Y12 inhibitor) and aspirin was more
effective than clopidogrel and aspirin, but with an
increased number of bleeding events (57).
Both prasugrel and ticagrelor seem to be good al-
ternatives to clopidogrel in patients with AF under-
going PCI because they inhibit platelets more
potently and show less interindividual variability
than clopidogrel. But both the PLATO and TRITON–
TIMI 38 trials excluded patients with VKA. In a pro-
spective registry of 377 patients, the combination of
prasugrel, aspirin, and VKA was used by 21 patients
and showed a 4-fold increase in the risk of TIMI minor
and major bleeding compared with a regimen of clo-
pidogrel, aspirin, and VKA, without any signiﬁcant
difference in efﬁcacy (75). We do not have any data
yet on the combinations of VKA plus prasugrel, VKA
plus ticagrelor, or triple therapy (VKA plus ticagrelor
plus aspirin) in AF patients undergoing PCI, but one
could reasonably fear that combining these more
potent platelet inhibitors with VKA could lead to
more bleeding events.
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1277Over the last decade, non-VKA oral anticoagulants
(NOACs) such as dabigatran, rivaroxaban, and apix-
aban have been shown to offer advantages over VKA
for stroke prevention in patients with AF (76–79).
Their potential as antithrombotic therapy after
ACS has as subsequently been investigated. The
ATLAS ACS 2-TIMI 51 (Anti-Xa Therapy to Lower
Cardiovascular Events in Addition to Standard
Therapy in Subjects with Acute Coronary Syndrome–
Thrombolysis IN Myocardial Infarction trial, for
example, showed that by adding low-dose rivarox-
aban in 15,526 patients with a recent ACS, the com-
posite endpoint of cardiac death, MI, and stroke was
reduced, whereas the risk of major and intracranial
bleeding was simultaneously increased (32). The
APPRAISE 2 (Apixaban for Prevention of Acute
Ischemic Events 2) trial, in which full-dose apixaban
was added to dual antiplatelet therapy in patients with
ACS, was halted prematurely, however, due to an
excess in major bleeding events without a signiﬁcant
reduction in ischemic events (33). In the REDEEM
(RandomizEd Dabigatran Etexilate Dose Finding
Study in Patients With Acute Coronary Syndromes)
trial, dabigatran in addition to DAPT also resulted in a
dose-related increase in bleeding risk without reduc-
tion of ischemic clinical events (79).
In AF patients who need PCI, none of these NOACs
has been tested yet. As demonstrated by all of these
trials, ﬁnding the balance between reducing the risk
of thromboembolic events without excessively
increasing bleeding risk is difﬁcult. The challenge of
using NOACs in AF patients who need PCI is just as
difﬁcult. First of all, we encounter the problem of
ﬁnding the optimal NOAC dose for this indication;
and second, we have to ponder which P2Y12 inhibitor
to prescribe and whether or not to combine it with
aspirin. PIONEER AF-PCI (An Open-label, Random-
ized, Controlled, Multicenter Study Exploring Two
Treatment Strategies of Rivaroxaban and a Dose-
Adjusted Oral Vitamin K Antagonist Treatment
Strategy in Subjects With Atrial Fibrillation Who Un-
dergo Percutaneous Coronary Intervention) is the
ﬁrst trial to address this issue, although the number
of different possibilities to investigate seems almost
unlimited (80). PIONEER AF-PCI is an innovative
phase IIb clinical study investigating the safety and
efﬁcacy of rivaroxaban in AF patients undergoing PCI.This study aims to include 2,100 patients to compare
the safety of 2 rivaroxaban treatment strategies
versus a dose-adjusted VKA treatment strategy. Pa-
tients will be treated for 12 months, and the primary
endpoint is the composite of TIMI major bleeding,
TIMI minor bleeding, and bleeding requiring medical
attention (80). The RE-DUAL PCI (Randomized Eval-
uation of Dual Therapy with Dabigatran vs. Triple
Therapy Strategy with Warfarin in Patients with
NVAF that have undergone PCI with Stenting) trial
was also started recently. In this trial, the safety and
efﬁcacy of 2 dabigatran treatment strategies will be
tested versus dose-adjusted VKA treatment (81). Un-
fortunately, the superior arm of the WOEST trial (VKA
and clopidogrel) was left out of both trials (80,81).
Another trial that is still recruiting patients is the
ISAR TRIPLE (Intracoronary Stenting and Anti-
thrombotic Regimen: Testing of a Six-Week Versus a
Six-Month Clopidogrel Treatment Regimen in Pa-
tients With Concomitant Aspirin and Oral Anticoag-
ulant Therapy Following Drug-Eluting Stenting) trial
in which 600 patients are randomized to a 6-week
versus a 6-month triple therapy regimen after DES
implantation. The primary endpoint of ISAR TRIPLE
is a net clinical beneﬁt endpoint consisting of MACCE
and major bleeding (82).
CONCLUSIONS
The efﬁcacy of triple therapy (VKA, aspirin, and clo-
pidogrel) in AF patients who need to undergo PCI
with stent placement has never been proven, but this
strategy increases bleeding risk signiﬁcantly. New
evidence, including a randomized controlled trial and
a real-life nationwide registry of more than 12,000
patients, showed the great potential of the combina-
tion of VKA and clopidogrel without aspirin to
improve clinical outcomes in comparison with triple
therapy. Therefore, VKA combined with clopidogrel
seems to be a reasonable alternative to triple therapy
in patients on long-term VKA who undergo PCI and
stenting.
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